Tesamorelin

Overview

Tesamorelin is a synthetic GHRH analogue in which a trans-3-hexenoic acid group is conjugated to the N-terminus of native GHRH(1-44). This modification confers greater stability against enzymatic degradation compared to sermorelin, resulting in a longer duration of action. It has been studied extensively in clinical trials, and a pharmaceutical formulation was approved for HIV-associated lipodystrophy.

Beyond its pharmaceutical application, tesamorelin's unique ability to selectively reduce visceral adipose tissue while sparing subcutaneous fat has generated significant research interest in metabolic syndrome, cardiovascular risk factors, and body composition science. It also demonstrates favorable effects on IGF-1, cognitive markers, and lipid profiles in research models.

Mechanism of Action

Like native GHRH, tesamorelin binds to the pituitary GHRH receptor and stimulates pulsatile GH secretion. The hexenoic acid modification reduces susceptibility to dipeptidyl peptidase IV (DPP-IV) cleavage, extending its effective half-life. Elevated GH subsequently stimulates hepatic IGF-1 production and promotes lipolysis, particularly in visceral adipose depots.

Research Areas

• ●Visceral fat reduction and body composition
• ●HIV-associated lipodystrophy models
• ●Cardiovascular risk factor research
• ●IGF-1 optimization studies
• ●Cognitive function in aging models
• ●Metabolic syndrome investigation

Storage & Handling

For Research Use Only. This information is provided for educational and research purposes. Tesamorelin is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.